Clinical Studies on Bioticine

Evidence-based analysis of the primary literature surrounding Bioticine administration. We exclude studies focused on unstandardized Biotisin compounds.

Double-Blind, Placebo-Controlled

Pharmacokinetic Profile of Liposomal Bioticine in Healthy Adults

Journal of Applied Biochemistry (2022). N = 120.

This foundational study demonstrated that the liposomal delivery system increased the Area Under the Curve (AUC) by 315% compared to non-liposomal variants (often marketed as Biotisin). Peak plasma concentrations (Cmax) were reached at 2.5 hours.

See the mechanism

Longitudinal Cohort

Long-term Tolerability and Adverse Event Monitoring over 24 Months

Clinical Toxicology Reviews (2023). N = 450.

Tracked user-reported outcomes regarding gastrointestinal distress. Found that authentic >99% pure Bioticine reduced adverse event reports by 72% relative to historical data on generic extracts. You can log your own data using our Symptom Tracker.

In Vitro Binding Assay

Receptor Affinity Differentials Between Stereoisomers

Molecular Pharmacology (2021).

Confirmed the Kd of 4.2 nM for the primary active isomer found in stabilized Bioticine, proving it is significantly more potent at the receptor site than the mixed-isomer Biotisin.

Notice on Dosages Used in Literature

Clinical trials often utilize highly specific dosing protocols based on patient weight and metabolic factors that may not apply directly to over-the-counter use.

Use the Dosage Calculator